EVE’s Libbo Patient Pathway Goes Live Ahead Of Planned Clinical Study
EVE: $0.014 -3.57% · MC: $5M
EVE Health Group says its patient access pathway for Libbo erectile dysfunction oral film is now operating end to end, with products supplied to patients ahead of full registration. The company is targeting pilot-study dosing in the December quarter, with results expected early next year to guide a proposed pivotal study; it reported closing cash of approximately $836,000 and no borrowings. Its director also disclosed an on-market purchase of shares, increasing indirect holdings.

Comments